Skip to main content
Premium Trial:

Request an Annual Quote

Cynthia Collins

DermTech, a developer of non-invasive molecular dermatology tests, has appointed Cynthia Collins to its board of directors. Collins most recently served as CEO of Human Longevity. She has also been CEO/GM of GE Healthcare's cell therapy business, lab businesses, and Clarient Diagnostics. Prior to GE, Collins was president and CEO of GenVec. Before that she was group vice president for the cellular analysis business at Beckman Coulter. She has also held executive positions with Sequoia Pharmaceuticals and Clinical Micro Sensors, a subsidiary of Motorola.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.